

המינהל לטכנולוגיות רפואיות ותשתיות אגף הרוקחות | המחלקה לרישום תכשירים רפואיים Drug Registration Department

כ״א אדר א, תשפ״ב 22 פברואר, 2022 סימוכין: 255652022

לכבוד בעלי רישום

הנדון: עדכון פורמט מכתב סיכום להגשת בקשות לרישום תכשירים חדשים ותוספות התוויה

בהמשך לפיילוט עדכון פורמט מכתב סיכום עבור בקשות לרישום תכשירים חדשים ותוספות התוויה שהתקיים בנוגע לבקשות המוגשות לסל הבריאות במהלך שנת 2021, אנו מעבירים להערותיכם את המסמכים העדכניים בהם הוטמעו הערות בעלי הרישום שהשתתפו בפיילוט.

מסמך זה יחליף את מכתב הסיכום הנדרש כיום בהתאם לנוהל להגשת בקשות לרישום, שינוי וחידוש תכשירים רפואיים (REG 08 2012).

הגשת המסמך בהתאם להנחיות ועם כלל המידע הנדרש בו, תסייע בידי בעלי הרישום לוודא את כי ההגשה תקינה וכוללת את הנתונים המלאים.. מעבר לכך, המסמך מאפשר לצוות המחלקה לקצר את תהליך הטיפול בבקשה וכן מסייע ליועצים חיצוניים של המחלקה במתן חוות דעת בנוגע לבקשה.

מסמך מסוג זה מקובל במספר רשויות מוכרות כחלק מהגשת בקשות לרישום ומאפשר לרשויות תהליך עבודה יעיל ומהיר יותר.

אנו מבינים כי הכנת המסמך דורשת השקעת זמן נוספת, אולם מבקשים את שיתוף הפעולה שלכם, על מנת לקצר את זמן הטיפול בבקשות השונות וכן לאפשר לצוות המחלקה לטפל בבקשות רבות יותר.

אנא העבירו הערותיכם למסמכים המצורפים עד לתאריך 16.03.2022 לידי הגבי אפרת ניסן בדואייל . EFRAT.NISAN@MOH.GOV.IL

בברכה,

02

דייר דניז אינבינדר

מנהלת המחלקה לרישום תכשירים

Drug Registration Department Ministry of HealthP.O.B 1176 Jerusalem 91010

call.habriut@moh.health.gov.il **Tel: -025080254 Fax: 02-6474866**

02-5080261 02-5080253 קול הבריאות *5400

המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 (פקס: 02-5080254 טל: 02-5080261



: העתק

המינהל לטכנולוניות רפואיות ותשתיות אגף הרוקחות | המחלקה לרישום תכשירים רפואיים Drug Registration Department

מגר׳ הדס רותם, מנהלת אגף הרוקחות מגר׳ אלי מרום, סגן מנהלת אגף הרוקחות

דייר עפרה אקסלרוד, מנהלת המכון לביקורת ותקנים של חומרי רפואה, וסגנית מנהלת אגף הרוקחות צוות המחלקה לרישום תכשירים

Drug Registration Department Ministry of Health

P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il Tel: -025080254 Fax: 02-6474866

02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 :פקס 02-5080254 טל: 02-5080261 02-5080253





Checklist for Submission of New Medicinal Product Application

1.	BAC	KGROUND INFORMATION					
	1.1	Product Name and additional names for the product used in the CTD					
	1.2	Applicant (MAH)					
	1.3	Active Ingredient and strength/dosage					
	1.4	Pharmaceutical Form					
	1.5	Method of Administration					
	1.6	The dossier submitted to Israel is identical to that submitted to					
	1.7	Registration Pathway in the reference country (regular/special/accelerated pathways)					
	1.8	Review pathway (270/180 days)					
	1.9	Requested Indication					
		As approved by(regulatory authority approved identical wording)					
	1.10	Requested posology					
		(for general population; indicate whether the posology during the supportive clinical trial differs from the requested posology)					
	1.11	Regulatory status					
		Including Approvals/Rejections/withdrawals/Appeals where relevant.					

Drug Registration Department Ministry of Health

P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il Tel: -025080254 Fax: 02-6474866

> 02-5080261 02-5080253



ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 (פקס: 02-5080254 טל: 02-5080261





Approvals

Country	Submission Date	Approval Date	Indication	

Submissions (under evaluation)

Country	Submitted Date	Proposed Indication

Withdrawals

Country	Submission Date	Withdrawal Date	Proposed Indication

Rejections

Country	Submission Date	Rejection Date	Proposed Indication

In cases where:

- the wording of the approved indication is different from the requested indication
- different wording was approved by regulatory agencies of recognized countries the reasons for the difference should be stated

For Rejections/withdrawals/Appeals, the deficiency letter, which led to the withdrawal/rejection, as well as the applicant's position to major objections should be submitted and major points should be shortly indicated in this checklist.

Drug Registration Department Ministry of HealthP.O.B 1176 Jerusalem 91010

call.habriut@moh.health.gov.il **Tel: -025080254 Fax: 02-6474866**

02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל: 02-5080261





2. DECISION CONTEXT

- 2.1 Short description of the disease (up to 3/4 page)
 (mechanism, prevalence...)
 Also, please indicate the file name and pages where the information is located
- 2.2 **Mechanism of action** (up to 3/4 page)

 Also, please indicate the file name and pages where the information is located
- 2.3 Unmet medical need including reference to treatments available in Israel for the requested indication (up to 3/4 page).
- 2.4 **Product specific relevant guidelines**ICH, EMA, FDA guidelines re efficacy/safety (not general guidelines, e.g.GCP)
 File name and pages where the information is located

3. QUALITY AND PRE-CLINICAL DATA

3.1 Justification for variation in formulation between the submitted final product as compared to products used in clinical studies and bridging data available

Also, please indicate the file name and pages where the information is located

3.2 Justification for differences in strength or presentation of the submitted final product as compared to products used in clinical studies

Also, please indicate the file name and pages where the information is located

4. EFFICACY BASED ON CLINICAL STUDIES SUBMITTED

Data from CSR in Module 5 and population/pool analyses from summary of clinical efficacy [2.7.3] should be used.

4.1 Summary of the studies supporting efficacy

A table should be included with details regarding the type of the study, number of patients, treatments, duration, objectives and endpoints.

Also, please Indicate file name and pages where the information is located.

Drug Registration Department Ministry of HealthP.O.B 1176 Jerusalem 91010

call.habriut@moh.health.gov.il **Tel: -025080254 Fax: 02-6474866**

02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל: 02-5080261





4.2 Details of clinical studies (pivotal and supportive) assessing efficacy

- Study name / Ref No.
- Study Design

A scheme/table demonstrating the study design could be presented.

- number of participants and population demographics (such as age and gender, other parameters only if relevant)
- o treatments, posology and following period
- o inclusion criteria as age/gender/stage of disease
- o <u>exclusion criteria</u>
- o study objectives
- primary and secondary endpoints

	· · · · · · · · · · · · · · · · · · ·
•	study start date:
•	study end date:
•	for ongoing study: date of next cut off, date of last cut-off
•	Date of clinical overview:
•	Date of CSR:
_	Poculto (nor study)

Results (per study)

detailed results for each endpoint including statistical significance (in case of non-significant results, discussion of their impact on efficacy) efficacy in special populations such as:

- gender
- age- including children, adolescents and elderly
- o renal impairment
- o hepatic impairment

(in case of lack of data in relevant populations, the basis for extrapolation to the specific population)

Short efficacy conclusions of the study

Also, please Indicate file name and pages where the information is located.

Drug Registration Department Ministry of HealthP.O.B 1176 Jerusalem 91010


call.habriut@moh.health.gov.il
Tel: -025080254 Fax: 02-6474866

02-5080261 02-5080253



ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל: 02-5080261





4.3 Efficacy conclusions (regarding all efficacy studies)

Summary of main issues and findings regarding efficacy from all studies mentioned above supporting efficacy, and a final conclusion regarding the efficacy profile.

Also, please Indicate file name and pages where the information is located.

5. SAFETY BASED ON CLINICAL STUDIES SUBMITTED

Data from CSR in Module 5 and population/pool analyses from summary of clinical safety [2.7.4]

5.1 Summary of the clinical studies/pools supporting safety

<u>Table/list</u> of the supporting studies (study number, number of patients per study...), number of patients in the safety data/pool (from Module 2) For each study/pool, the following information should be included:

- number of patients treated
- following period
- posology
- safety endpoints

Also, please Indicate file name and pages where the information is located.

5.2 Details of the clinical studies/pools supporting safety (per study/pool)

- ADR's Reported: serious, severe, common, very common and incidence (could be presented in a table)
- Detailed serious and severe adverse events
- Discontinuation rates, including deaths
- Adverse events of special interest
- Applicant's assessment regarding significant differences between the test group and the control group in safety profile

Drug Registration Department Ministry of Health

P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il Tel: -025080254 Fax: 02-6474866


> 02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל: 02-5080261





Safety in special populations:

- gender
- age- including children, adolescents and elderly
- renal impairment
- hepatic impairment
- pregnancy
- breastfeeding
- fertility
- any other relevant special populations
- Short safety conclusion

Also, please Indicate file name and pages where the information is located.

5.4 Safety conclusions

Summary of main issues and findings regarding safety, including differences in safety profile between control and treatments groups and a final conclusion regarding the safety profile.

Also, please Indicate file name and pages where the information is located.

5.5 Summary of safety concerns and risk minimization measures (additional pharmacovigilance activities and additional risk minimization measures)

Based on RMP (dated from...) (or core RMP if RMP was yet approved by regulatory agency of recognized country).

Table with summary of Safety Concerns (identified and potential risks and missing information) from RMP should be inserted.

Also, please Indicate file name and pages where the information is located.

Drug Registration Department Ministry of HealthP.O.B 1176 Jerusalem 91010

call.habriut@moh.health.gov.il
Tel: -025080254 Fax: 02-6474866

02-5080261 02-5080253







5.6	Summary of recent PSUR/PBRER (or PADER if PSUR/PBRER no	эt
	available), if available.	

- date of the report_____
- period of the report_____
- cumulative exposure from marketing experience_____
- conclusions and actions

6. IMPORTANT INFORMATION FROM OTHER REGULATORY AUTHORITIES

From assessment reports of two regulatory authorities of recognized countries, preferably EMA and FDA and the regulatory authority where the application was rejected/withdrawn, where relevant, if available.

Assessment report by

Please address the following points:

- Uncertainties and special issues regarding safety and efficacy
- Efficacy conclusions
- Safety conclusions
- Missing information
- Deviations from guidelines
- o Effects table (if available)
- Uncertainties and limitations re unfavorable/favorable effects
- In case of rejection detailed explanation on the reasons for rejection by the regulatory authority
- Post marketing requirements, risk minimization measures (including dates for submission)
- 7. <u>ADDITIONAL DATA SUBMITTED (</u>any data not included in the CTD submitted to the reference country), where relevant
 - 7.1 Post marketing data
 - 7.2 Additional data from clinical studies (updated cut-off data and any other updates to the information supporting safety and/or efficacy submitted to any of the recognized countries)
 - 7.3 Additional relevant publications

Drug Registration Department Ministry of Health

P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il Tel: -025080254 Fax: 02-6474866

02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל:





Checklist for Application of New Indication for a Registered Medicinal Product

6.	BACI	KGROUND INFORMATION
	6.1	Product Name and additional names for the product used in the CTD
	6.2	Applicant (MAH)
	6.3	Active Ingredient and strength/dosage
	6.4	Pharmaceutical Form
	6.5	Method of Administration
	6.6	The dossier submitted to Israel is identical to that submitted to
	6.7	Registration Pathway in the reference country (regular/special/accelerated pathways)
	6.8	Review pathway (270/180 days)
	6.9	Currently approved indication in Israel
	6.10	Requested Indication
		As approved by(regulatory authority approved identical wording)
	6.11	Currently approved posology in Israel
	0.40	(for general population)
	6.12	Requested posology
		(for general population; indicate whether the posology during the supportive

Drug Registration Department Ministry of Health

P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il Tel: -025080254 Fax: 02-6474866

02-5080261 02-5080253




clinical trial differs from the requested posology)

המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 (פקס: 02-5080254 טל: 02-5080261





6.13 Regulatory status

Including Approvals/Rejections/withdrawals/Appeals where relevant.

Approvals

1970				
Country	Submission Date	Approval Date	Indication	

Submissions (under evaluation)

Country	Submitted Date	Proposed Indication

Withdrawals

Country	Submission Date	Withdrawal Date	Proposed Indication

Rejections

Country	Submission Date	Rejection Date	Proposed Indication

In cases where:

- the wording of the approved indication is different from the requested indication
- different wording was approved by regulatory agencies of recognized countries

Drug Registration Department Ministry of Health P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il

Tel: -025080254 Fax: 02-6474866

02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל: 02-5080261





the reasons for the difference should be stated

For Rejections/withdrawals/Appeals, the deficiency letter, which led to the withdrawal/rejection, as well as the applicant's position to major objections should be submitted and major points should be shortly indicated in this checklist.

7. <u>DECISION CONTEXT</u>

- 7.1 **Short description of the disease** (up to 3/4 page) (mechanism, prevalence...)

 Also, please indicate the file name and pages where the information is located
- 7.2 **Mechanism of action** (up to 3/4 page)

 Also, please indicate the file name and pages where the information is located
- 7.3 Unmet medical need including reference to treatments available in Israel for the requested indication (up to 3/4 page).
- 7.4 **Product specific relevant guidelines**ICH, EMA, FDA guidelines re efficacy/safety (not general guidelines, e.g.GCP)
 File name and pages where the information is located

8. QUALITY AND PRE-CLINICAL DATA

- 8.1 Justification for variation in formulation between the submitted final product as compared to products used in clinical studies and bridging data available
 - Also, please indicate the file name and pages where the information is located
- 8.2 Justification for differences in strength or presentation of the submitted final product as compared to products used in clinical studies

 Also, please indicate the file name and pages where the information is located

Drug Registration Department Ministry of Health

P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il Tel: -025080254 Fax: 02-6474866

> 02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל: 02-5080261





9. EFFICACY BASED ON CLINICAL STUDIES SUBMITTED

Data from CSR in Module 5 and population/pool analyses from summary of clinical efficacy [2.7.3] should be used.

9.1 Summary of the studies supporting efficacy

A table should be included with details regarding the type of the study, number of patients, treatments, duration, objectives and endpoints.

Also, please Indicate file name and pages where the information is located.

9.2 Details of clinical studies (pivotal and supportive) assessing efficacy

- Study name / Ref No.
- Study Design

A scheme/table demonstrating the study design could be presented.

- number of participants and population demographics (such as age and gender, other parameters only if relevant)
- treatments, posology and following period
- o inclusion criteria as age/gender/stage of disease
- o exclusion criteria
- study objectives
- o primary and secondary endpoints

•	study start date:
•	study end date:
•	for ongoing study: date of next cut off, date of last cut-off
•	Date of clinical overview:
•	Date of CSR:

• Results (per study)

detailed results for each endpoint including statistical significance (in case of non-significant results, discussion of their impact on efficacy) efficacy in special populations such as:

- gender
- o age-including children, adolescents and elderly
- o renal impairment
- hepatic impairment

Drug Registration Department Ministry of Health P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il

Tel: -025080254 Fax: 02-6474866


02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 מ.ד.call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל:





(in case of lack of data in relevant populations, the basis for extrapolation to the specific population)

Short efficacy conclusions of the study

Also places Indicate file name and pages where the inferior

Also, please Indicate file name and pages where the information is located.

9.3 Efficacy conclusions (regarding all efficacy studies)

Summary of main issues and findings regarding efficacy from all studies mentioned above supporting efficacy, and a final conclusion regarding the efficacy profile.

Also, please Indicate file name and pages where the information is located.

10. SAFETY BASED ON CLINICAL STUDIES SUBMITTED

Data from CSR in Module 5 and population/pool analyses from summary of clinical safety [2.7.4]

10.1 Summary of the clinical studies/pools supporting safety

<u>Table/list</u> of the supporting studies (study number, number of patients per study...), number of patients in the safety data/pool (from Module 2) For each study/pool, the following information should be included:

- number of patients treated
- following period
- posology
- safety endpoints

Also, please Indicate file name and pages where the information is located.

10.2 Details of the clinical studies/pools supporting safety (per study/pool)

- ADR's Reported: serious, severe, common, very common and incidence (could be presented in a table)
- Detailed serious and severe adverse events
- Discontinuation rates, including deaths
- Adverse events of special interest
- Applicant's assessment regarding significant differences between the test group and the control group in safety profile

Drug Registration Department Ministry of Health

P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il Tel: -025080254 Fax: 02-6474866

> 02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל:





Safety in special populations:

- gender
- age- including children, adolescents and elderly
- renal impairment
- hepatic impairment
- pregnancy
- breastfeeding
- fertility
- any other relevant special populations
- Short safety conclusion

Also, please Indicate file name and pages where the information is located.

7.4 Safety conclusions

Summary of main issues and findings regarding safety, including differences in safety profile between control and treatments groups and a final conclusion regarding the safety profile.

Also, please Indicate file name and pages where the information is located.

7.5 Summary of safety concerns and risk minimization measures (additional pharmacovigilance activities and additional risk minimization measures)

Based on RMP (dated from...) (or core RMP if RMP was yet approved by regulatory agency of recognized country).

Table with summary of Safety Concerns (identified and potential risks and missing information) from RMP should be inserted.

Also, please Indicate file name and pages where the information is located.

7.6	Summary of recent PSUR/PBRER (or PADER if PSUR/PBRER not
	available), if available.

•	date of the report
•	period of the report
•	cumulative exposure from marketing experience
•	conclusions and actions

Drug Registration Department Ministry of Health P.O.B 1176 Jerusalem 91010 call.habriut@moh.health.gov.il

Tel: -025080254 Fax: 02-6474866

02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל:





8. IMPORTANT INFORMATION FROM OTHER REGULATORY AUTHORITIES

From assessment reports of two regulatory authorities of recognized countries, preferably EMA and FDA and the regulatory authority where the application was rejected/withdrawn, where relevant, if available.

Assessment report by

Please address the following points:

- o Uncertainties and special issues regarding safety and efficacy
- Efficacy conclusions
- Safety conclusions
- Missing information
- Deviations from guidelines
- Effects table (if available)
- Uncertainties and limitations re unfavorable/favorable effects
- In case of rejection detailed explanation on the reasons for rejection by the regulatory authority
- Post marketing requirements, risk minimization measures (including dates for submission)
- 9. <u>ADDITIONAL DATA SUBMITTED (</u>any data not included in the CTD submitted to the reference country), where relevant
 - 7.4 Post marketing data
 - 7.5 Additional data from clinical studies (updated cut-off data and any other updates to the information supporting safety and/or efficacy submitted to any of the recognized countries)
 - 7.6 Additional relevant publications

Drug Registration Department Ministry of HealthP.O.B 1176 Jerusalem 91010

call.habriut@moh.health.gov.il
Tel: -025080254 Fax: 02-6474866

02-5080261 02-5080253



המחלקה לרישום תכשירים רפואיים משרד הבריאות

ת.ד.1176 ירושלים 91010 call.habriut@moh.health.gov.il

02-6474866 פקס: 02-5080254 טל: 02-5080261